Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:05:40.148Z.
Calculation as of: 2026-10-06T12:05:40.148Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69328368594ca01c79a1d7ac3810be200bc4ff9949d0867bb2c2a7ab20a5f204
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Anavex Life Sciences Corp.
Market Cap
$152.45M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.16M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.84M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$142.49M
Price/OCF Ratio
1.13
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$162.82M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$134.74M
Price/OCF Ratio
105.51
TTM Avg
51.49
3Y Avg
30.98
5Y Avg
26.48
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $152.45M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A | 32.64 | 32.64 | 32.64 |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 1.13 | 4.90 | 4.90 | 4.90 |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | 105.51 | 51.49 | 30.98 | 26.48 |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
